ACTRN12620000954921已完成4 期
Efficacy of a prime-boost, double-dose immunisation of the seasonal influenza vaccination in COPD patients.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 50 Years 至 o limit（—）
- 性别
- All
入选标准
- •Mild to very Severe COPD with a post bronchiodilater FEV1 less than 80%.
- •Predicted FEV1/FVC ratio less than 0.8.
- •COPD patients will be stable with no COPD exacerbations or respiratory infections within the 4 weeks prior to participating in the study.
排除标准
- •Invasive malignancy within the last 2 years.
- •Renal impairment (eGFR less than 40 ml/min).
- •Acute febrile illness with fever greater than 38.5 degrees Celsius.
- •Hypersensitivity to egg protein.
- •Use of oral Prednisolone or equivalent. greater than or equal to 10 mg per day.
- •Use of other systemic immunosuppressive therapy.
- •Anaphylaxis following a previous dose of influenza vaccine.
- •Anaphylaxis following a vaccine component (including eggs).
- •History of Guilliane Barre within 6 weeks of a previous influenza vaccination
- •Non-stable cardiac disease, non-stable diabetes mellitus, and some skin cancers as assessed by the principal investigator,
研究者
相似试验
已完成
4 期
Intradermal second booster COVID-19 vaccinatioThe second booster intradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2.booster vaccine, SAR-CoV2, older adult, intradermal vaccination, elderly, ThailandTCTR20230411008Faculty of Medicine Siriraj hospital, Mahidol University107
进行中（未招募）
1 期
Study to Evaluate the Immune Response after a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly with a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W)MedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-004461-41-Outside-EU/EEASanofi Pasteur Inc570
进行中（未招募）
不适用
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Sanofi Pasteur's Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in MexicoPrevention of symptomatic dengue diseaseEUCTR2014-001736-11-Outside-EU/EEASanofi Pasteur SA732
已完成
1 期
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)VaccinePandemic Influenza VaccinePreventionPandemic InfluenzaNCT00660257Sinovac Biotech Co., Ltd57
招募中
4 期
Efficacy of ketamine in the treatment of depressive disorderBipolar disorderIRCT20101130005280N58Mashhad University of Medical Sciences60